title: The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates.
abstract: Anakinra improves the central nervous system manifestations of neonatal-onset multisystem inflammatory disease, which is mediated by IL-1beta oversecretion. The cerebrospinal fluid (CSF) penetration of the IL-1 receptor antagonist anakinra was studied in rhesus monkeys after intravenous doses of 3 and 10 mg/kg. Drug exposure (area under concentration-time curve) in CSF was 0.28% of that in serum. The average CSF concentration at 3 mg/kg was 1.8 ng/mL, which is 30-fold higher than endogenous CSF levels of IL-1Ra. The CSF penetration was not dose-dependent, indicating that the CSF penetration was not saturated in the 3 to 10 mg/kg dose range.
authors.affiliation: The Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA 19104, USA. Foxe@email.chop.edu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fox
authors.forename: Nalini
authors.initials: N
authors.lastname: Jayaprakash
authors.forename: Tuyet-Hang
authors.initials: TH
authors.lastname: Pham
authors.forename: Ayana
authors.initials: A
authors.lastname: Rowley
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: McCully
authors.forename: Frank
authors.initials: F
authors.lastname: Pucino
authors.forename: Raphaela
authors.initials: R
authors.lastname: Goldbach-Mansky
mesh_terms: D000818:Animals; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics* / Q000592:standards; D008253:Macaca mulatta; D008297:Male
chemical_list: D053590:Interleukin 1 Receptor Antagonist Protein